Market Overview

I think you’ll love what you hear,
what you’ll see and the opportunities
that will be set before you.
- Jon Najarian

Wedbush Securities Sees Preparations Continuing For Expected Approval And Strong Launch Of Kanuma For Synageva Biopharma


In a report published Friday, Wedbush Securities analyst David M. Nierengarten reiterated an Outperform rating and $111.00 price target on Synageva Biopharma Corp. (NASDAQ: GEVA).

In the report, Wedbush Securities noted, "GEVA reported Q4:14 EPS of ($1.73), slightly below our estimate of ($1.67) and consensus of ($1.71). The company ended the quarter with $447M in cash and cash equivalents, not including proceeds from the recent follow-on offering of $309M, and guided towards 2015 total operating expenses of between $280M and $295M. We had previously estimated operating expenses to be approximately $240M, with the increase likely reflecting additional investment in Kanuma's launch later this year, in part by focusing on patient identification programs."

Synageva Biopharma closed on Thursday at $99.42.

Latest Ratings for GEVA

May 2015DowngradesOutperformNeutral
Mar 2015DowngradesOverweightNeutral
Feb 2015MaintainsNeutral

View More Analyst Ratings for GEVA
View the Latest Analyst Ratings

Posted-In: David M. Nierengarten Wedbush SecuritiesAnalyst Color Reiteration Analyst Ratings


Related Articles (GEVA)

View Comments and Join the Discussion!

Latest Ratings

GRUBInitiates Coverage On
HOTHInitiates Coverage On
NDRAInitiates Coverage On
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Wedbush Securities Reiterates Outperform, Raises PT On Ross Stores As 2015 Appears Set To Deliver Continued EPS Beats

Lean Hogs Move Higher